Cargando…
Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy
Triple-negative breast cancers lack estrogen receptor α (ERα), progesterone receptor, and do not overexpress human epidermal growth factor receptor 2 (Her-2). They are neither susceptible to endocrine therapy nor to a therapy using the anti-Her-2 antibody, trastuzumab. Therefore, an efficient target...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397221/ https://www.ncbi.nlm.nih.gov/pubmed/22290080 http://dx.doi.org/10.1007/s10549-012-1968-x |